miR-146a-3p as a potential novel therapeutic by targeting MBD2 to mediate Th17 differentiation in Th17 predominant neutrophilic severe asthma.

Abstract

Th17 (T-helper 17) cells subtype of non-T2 (non-type 2) asthma is related to neutrophilic infiltration and resistance to inhaled corticosteroids (ICS), so is also known as severe asthma. Methyl-CpG binding domain protein 2 (MBD2) regulates the differentiation of the Th17 cells, tending to show a therapeutic target in severe asthma. miR-146a-3p is associated with anti-inflammatory characteristics and immunity. Moreover, bioinformatic analysis showed that MBD2 may be a target gene of miR-146a-3p. However, the role of miR-146a-3p in the differentiation of Th17 cells via MBD2 in severe asthma remains unknown. Here, we aimed to explore how miR-146a-3p interacts with MBD2 and affects the differentiation of Th17 cells in severe asthma. First, we recruited 30 eligible healthy people and 30 patients with severe asthma to detect the expression of miR-146a-3p in peripheral blood mononuclear cells (PBMCs) by qRT-PCR. Then, we established a HDM/LPS (house dust mite/lipopolysaccharide) exposure model of bronchial epithelial cells (BECs) to evaluate the expression of miR-146a-3p, the interaction between miR-146a-3p and MBD2 using western blot and luciferase reporter analysis and the effect of miR-146a-3p regulated Th17 cells differentiation by flow cytometry in BECs in vitro. Finally, we constructed a mouse model of Th17 predominant neutrophilic severe asthma to assess the therapeutic potential of miR-146a-3p in severe asthma and the effect of miR-146a-3p regulated Th17 cells differentiation via MBD2 in vivo. Decreased miR-146a-3p expression was noted in severe asthma patients, in the BECs and in the animal severe asthma models. Moreover, we demonstrated that miR-146a-3p suppressed Th17 cells differentiation by targeting the MBD2. miR-146a-3p overexpression significantly reduced airway hyperresponsiveness, airway inflammation and airway mucus secretion, while also inhibiting Th17 cells response in vivo, which relieved severe asthma. By targeting MBD2 to suppress Th17 cells differentiation, miR-146a-3p provides a potential novel therapeutic for Th17 predominant neutrophilic severe asthma.

• Authors: Wentao Duan, Jin Huang, Binaya Wasti, Zhifeng Chen, Yu Yuan, Yi He, Danhong Li, Jingsi Jia, Shaokun Liu, Yi Liu, Libing Ma, Qingping Zeng, Liming Zhu, Jianmin Li, Xiufeng Zhang, Xudong Xiang
• Journal: Clinical and experimental medicine (Clin Exp Med) Vol. 23 Issue 6 Pg. 2839-2854 (Oct 2023) ISSN: 1591-9528 [Electronic] Italy
• PMID: 36961677 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• DNA-Binding Proteins
• MBD2 protein, human
• MicroRNAs
• Mbd2 protein, mouse
• Mirn146 microRNA, mouse
• MIRN146 microRNA, human

Topics

• Animals
• Humans
• Mice
• Asthma (drug therapy, genetics)
• Cell Differentiation (genetics)
• DNA-Binding Proteins (genetics)
• Leukocytes, Mononuclear
• MicroRNAs (genetics)
• Th17 Cells